Page last updated: 2024-08-22

sizofiran and Neoplasms

sizofiran has been researched along with Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Izumi, H; Sakurai, K; Sumiya, K1
Aoshi, T; Ishii, KJ; Kobiyama, K; Mochizuki, S; Morishita, H; Sakurai, K1
Aoshi, T; Coban, C; Hayashi, M; Ishii, KJ; Kanuma, T; Kitahata, Y; Kobayashi, N; Kobiyama, K; Kuroda, E; Kusakabe, T; Ozasa, K; Temizoz, B; Yamamoto, T; Yamaue, H1
Rowan, NJ; Smith, JE; Sullivan, R1
Borchers, AT; Gershwin, ME; Hackman, RM; Keen, CL; Stern, JS1

Reviews

2 review(s) available for sizofiran and Neoplasms

ArticleYear
Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine.
    Perspectives in biology and medicine, 2006,Spring, Volume: 49, Issue:2

    Topics: Agaricales; Antineoplastic Agents; Chemistry, Pharmaceutical; Humans; Lentinan; Medicine, East Asian Traditional; Neoplasms; Plants, Medicinal; Polysaccharides; Proteoglycans; Sizofiran

2006
Mushrooms, tumors, and immunity.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1999, Volume: 221, Issue:4

    Topics: Adjuvants, Immunologic; Agaricales; Animals; Antineoplastic Agents; beta-Glucans; Dextranase; Dietary Supplements; Glucans; Humans; Lentinan; Macrophages; Mice; Monocytes; Neoplasms; Sizofiran; T-Lymphocytes

1999

Other Studies

3 other study(ies) available for sizofiran and Neoplasms

ArticleYear
Enhanced Therapeutic Efficacy of Immunostimulatory CpG-ODN by Silencing SOCS-1 with Polysaccharide/miR-155 Complexes.
    ACS applied bio materials, 2023, 02-20, Volume: 6, Issue:2

    Topics: Adjuvants, Immunologic; Animals; Immunization; Mice; MicroRNAs; Neoplasms; Oligodeoxyribonucleotides; Sizofiran; Suppressor of Cytokine Signaling 1 Protein; Toll-Like Receptor 9

2023
Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
    Journal of controlled release : official journal of the Controlled Release Society, 2015, Dec-28, Volume: 220, Issue:Pt A

    Topics: Adjuvants, Immunologic; Animals; Antigen-Presenting Cells; Cancer Vaccines; Cells, Cultured; Immunization; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Mice, Inbred C57BL; Neoplasms; Oligodeoxyribonucleotides; Ovalbumin; Peptide Fragments; Sizofiran; Spleen; T-Lymphocytes, Cytotoxic; Tissue Distribution; Tumor Burden

2015
Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.
    Oncotarget, 2016, Aug-02, Volume: 7, Issue:31

    Topics: Adjuvants, Immunologic; Animals; Antibody Formation; CD8-Positive T-Lymphocytes; CpG Islands; Cytokines; Humans; Immunity, Innate; Interferon Type I; Interferon-gamma; Interleukin-12; Leukocyte Common Antigens; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nanoparticles; Neoplasms; Oligodeoxyribonucleotides; Phagocytosis; Sizofiran; Toll-Like Receptor 9; Tumor Microenvironment

2016